Ibrutinib for Chronic Lymphocytic Leukemia

Authors:
  • JBJan A Burger
    Jan A Burger
  • LSLori Styles
    Lori Styles
  • TKThomas J Kipps
    Thomas J Kipps

Abstract
To the Editor: It is not surprising that Burger et al. (Dec. 17 issue)1 report positive results in the Study of Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia (RESONATE-2), a randomized trial of ibrutinib versus chlorambucil in older patients with chronic lymphocytic leukemia (CLL). Chlorambucil has served as a comparator in trials of bendamustine, alemtuzumab, ofatumumab, and obinutuzumab, and longer durations of progression-free survival have been reported with each agent.25 In addition, these trials have shown longer durations of overall survival with the use of ibrutinib and obinutuzumab.1,2We reviewed our experience in the Connect . . .

This publication has 9 references indexed in Scilit: